sales@contrivedatuminsights.com
CDI - Contrive Datum Insights
Press ReleaseMedical Devices

Ivf Syringes Market Forecast to USD 3.2 billion by 2034, Growing 9.75% a Year

Subcutaneous Injection is the fastest-growing line at 10.94%; North America is the largest region at 34% of 2025 revenue.

PUNE, INDIA — 21 AUGUST 2026CONTRIVE DATUM INSIGHTS

From USD 1.38 billion in 2025 to USD 3.2 billion in 2034, a 9.75% compound annual rate.

34% of 2025 revenue (USD 0.47 billion) is generated in North America.

Subcutaneous Injection is the fastest-growing line at 10.94% annually.

62.32% of 2025 revenue sits in Subcutaneous Injection, the largest type line.

The global ivf syringes market was valued at USD 1.38 billion in 2025. The market is projected to grow from USD 1.52 billion in 2026 to USD 3.2 billion by 2034, exhibiting a compound annual growth rate of 9.75% during the forecast period. Contrive Datum Insights presents this information in its report titled "Ivf Syringes Market Size, Share & Industry Analysis, By Type (Subcutaneous Injection, Intramuscular Injection), Application (Fertility Clinics, Hospitals, Homecare Settings), Syringe design (Conventional Syringes, Prefilled Syringes), Material (Plastic/Polypropylene, Glass), Distribution channel (Direct/Institutional Sales, Retail Pharmacies, Online Pharmacies), and Regional Forecast, 2026-2034".

IVF syringes are the sterile, single-use injection devices used to draw and administer the hormone medications that support in vitro fertilization treatment, covering both intramuscular and subcutaneous formats designed to work with fertility drug formulations. They are purchased by fertility clinics, hospital reproductive medicine units, and increasingly by patients themselves for at-home self-administration of stimulation and luteal-support injections under a clinician's prescribed protocol.

Rising global infertility prevalence and delayed childbearing

Rising global infertility prevalence and delayed childbearing is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 9.75% a year, the type lines exposed to it move fastest: Subcutaneous Injection compounds at 10.94%, taking its share of revenue from 62.32% to 68.13% and its value from USD 0.86 billion to USD 2.18 billion.

On the upside, the study's bull case assumes bull case assumes reimbursement coverage for IVF expands in more countries and prefilled, home-administered formats gain share faster than in the base case, which would take 2034 revenue to USD 3.84 billion rather than the USD 3.2 billion base case.

However, bear case assumes reimbursement expansion stalls and out-of-pocket cost pressure slows IVF cycle-start growth in the largest markets, which would hold 2034 revenue to USD 2.64 billion. Intramuscular Injection, which carries 37.68% of 2025 revenue, already grows at only 7.55% against the market's 9.75%, so the largest part of the base is also its slowest.

Key Players Compete on Subcutaneous Injection Volume and Subcutaneous Injection Growth

Competition in the global ivf syringes market runs along the type axis rather than the regional one. Subcutaneous Injection holds 62.32% of 2025 revenue at USD 0.86 billion and remains the largest line through 2034 at 68.13%, making it the position hardest for a challenger to take. Subcutaneous Injection, growing at 10.94%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 1.38 billion.

Further Report Findings

SegmentLed 2025 byShare & valueFastest-growing
TypeSubcutaneous Injection62.32% · USD 0.86 billion
ApplicationFertility Clinics54.35% · USD 0.75 billionHomecare Settings 15.38%
Syringe designConventional Syringes57.97% · USD 0.8 billionPrefilled Syringes 12.4%
MaterialPlastic/Polypropylene71.01% · USD 0.98 billion
Distribution channelDirect/Institutional Sales65.94% · USD 0.91 billionOnline Pharmacies 15.45%
  • Based on regional analysis, North America led the global ivf syringes market in 2025 with 34% of global revenue at USD 0.47 billion, reaching USD 0.99 billion by 2034.
  • Asia Pacific takes a rising share of global revenue over the forecast period, from 26% in 2025 to 32% in 2034, with revenue growing from USD 0.36 billion to USD 1.02 billion.
  • Middle East and Africa remains the smallest region throughout, at 6% of 2025 revenue and 6% by 2034.
  • Subcutaneous Injection is projected to grow at 10.94% over the forecast period, the fastest of any type line.
  • The United States is the largest single country market at USD 0.4 billion in 2025, 29% of global revenue.

The report segments the market across five axes; by type, and by application, syringe design, material and distribution channel; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 2.64 billion and USD 3.84 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.

Regions Covered
North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa
About Contrive Datum Insights

Contrive Datum Insights is a global market intelligence and consulting firm working across investment, information technology, healthcare and manufacturing markets. Every market we publish is sized twice — once top-down from the leading players and once bottom-up from the addressable base — and validated by primary interview. More about CDI.

Asia Pacific
Kunjir Shyama Prestine, Sr. no. 174/1
Jagtap Diary Road, Pimple Saudagar
Pune 411017, India
+91 983 481 6757
United States
21C2 Lakeshore Dr.
Farmington, CT 06032
United States
+1 215 297 4078